Science 37 and UCB partner to improve clinical trial experience

8th May 2018 (Last Updated May 8th, 2018 00:00)

Science 37 has signed a strategic collaboration with global biopharmaceutical company UCB to improve clinical trial experience by facilitating more patient-friendly, technology-enabled trials at home.

Science 37 and UCB partner to improve clinical trial experience
New collaboration demonstrates full potential of decentralised clinical trials by being more representative of ‘real life’ settings, improving patient access and experience. Credit: Science 37, Inc.

Science 37 has signed a strategic collaboration with global biopharmaceutical company UCB to improve clinical trial experience by facilitating more patient-friendly, technology-enabled trials at home.

Under the collaboration, Science 37’s cloud-based mobile research platform, Network Oriented Research Assistant (NORA) will be used to offer greater patient value to the people participating in the trials conducted by UCB.

The decentralised approach of NORA is expected to provide data that will be more representative of patients' real-life experiences.

It further aims to reduce the duration of product development and allow the faster launch of certain treatments.

"We created Science 37 to uniquely combine telemedicine technology, decentralised physician networks, and in-house experienced clinical study staff."

Initially, the partnership will focus on the areas of neurology and immunology.

The partnership is also expected to enable a more integrated study design process where the patient-centric mindset will help early protocol development.

Science 37 co-founder and CEO Noah Craft said: “We created Science 37 to uniquely combine telemedicine technology, decentralised physician networks, and in-house experienced clinical study staff to take on new and exciting research studies."

The NORA platform is designed to allow end-to-end remote clinical trials and complies with the advanced industry quality and regulatory standards.

Science 37 has also developed the Metasite or ‘site-less’ model, which is designed to help researchers engage directly with trial participants through every stage of planning starting from screening and recruitment to data lock.

The model’s direct online connection enables greater retention of patients, increased diversity across trials, and faster recruitment.